Takeda-Abbott Deal Reflects New Realities Facing Japanese Drug Makers
This article was originally published in PharmAsia News
Executive Summary
Takeda's buyout of Abbott Laboratories' half of TAP Pharmaceutical Products reflects a new reality facing Japanese drug makers, according to an analysis. Japan's pharmaceutical business has been hampered by government efforts to lower health care spending at the same time population figures are declining. As a result, drug makers in the country are looking overseas for business expansion. Takeda has stepped up mergers and acquisitions abroad since last year, using the resources of foreign companies to supplant reduced business at home. (Click here for more - a subscription may be required